IDP.L

InnovaDerma Plc
InnovaDerma PLC - Interim Results
31st March 2022, 06:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 6799G
InnovaDerma PLC
31 March 2022
 

InnovaDerma PLC

("InnovaDerma" or the "Company")

Interim Results for the 6 months ended 31 December 2021

InnovaDerma (LSE: IDP), a leading digitally focused UK beauty brand developer, announces its unaudited half year results for the period ended 31 December 2021.

Financial Highlights

 

 

H1 2022

H1 20211

Change

 

 

 

 

Revenue2

£3.7m

£4.1m

(9.5%)

Gross profit

£2.1m

£2.0m

3.1%

Gross margin

56.3%

49.4%

690 bps

Adjusted EBITDA3

(£0.7m)

(£1.2m)

£0.5m

Basic EPS

(£0.03)

(£0.10)

£0.07

Cash and cash equivalents

£1.33m

£0.15m

£1.18m

 

1 See note 2.3 for a description of the prior year restatement.

2 On a constant currency basis

3 Adjusted EBITDA defined as EBITDA before non-recurring items, including impairments, abortive and restructuring costs. A reconciliation of adjusted EBITDA can be found in note 5 below.

 

Operational Highlights

 

Our strategy of driving increased profitable sales through gross margin improvement, radical simplification of business operations, rigorous cost control and the prioritisation of our Skinny Tan brand, is working.

 

Financial performance is markedly improved vs H1 2020. Our previously announced strategy has been implemented with a disciplined approach to marketing and overhead costs.

 

Short-term impact on revenue (revenues of c. £3.7m versus H1 20: £4.1m) primarily driven by ceasing loss-making sales promotions and reducing marketing investment in lower priority brands such as Nuthing.

 

Adjusted EBITDA improved significantly to £0.7m loss (H1 21 restated: £1.2m loss).

 

We have further improved our return on marketing spend to 38.1% (H1 21: 40.0%, H2 21: 39.2%) and have reduced less-efficient marketing spend during the low tanning season to ensure we have the right ammunition to maximise returns over the peak H2 tanning season (UK + US).

 

Our Liberty Poole collaboration continues to yield benefits and is helping to increase the share of our business in the key 18-25 age group.

 

Global Amazon relationship already delivering material sales in lead UK market at a healthy margin.

 

Enhanced e-commerce operational excellence with 76% of customers giving Skinnytan.co.uk 5 stars.

 

Joint venture agreement signed in December 2021 to accelerate sales of the Prolong medical device, with InnovaDerma plc retaining 45% stake in the business, and enabling the Group to focus on its topical products.

 

Outlook

 

The Board remains optimistic that the transformation plan enacted this year, as well as underlying improved consumer consumption and retail momentum versus last year will enable the business to continue its improvement trajectory over the second half year with a return to profitability this year remaining the Board's intention. The second half of our financial year has historically been considerably stronger than the first, driven by Skinny Tan in the UK, and this is expected to be the case again this year.  We continue to closely monitor residual impacts of COVID-19 and other global impacts on underlying beauty category consumption and we believe they will continue to improve towards the peak tanning season in the UK

 

Blake Hughes, CEO InnovaDerma plc, commented:

 

 

"We continue to make good progress in simplifying and reshaping our business as we focus on delivering sustainable, profitable revenue growth. It is pleasing to see that our strategy is delivering tangible financial improvements.

 

"We have a strong foundation for the second half of the year, especially as the focus on Amazon and our Liberty Poole collaboration are delivering strong benefits, even before peak tanning season. This will be supported by our well-honed digital capabilities and conversion optimised e-commerce site and exciting new Skinny Tan product launches which have already received excellent retailer support."

 

Further enquiries

InnovaDerma

Blake Hughes

 

c/o TB Cardew

finncap Ltd

Geoff Nash/Kate Bannatyne

Alice Lane - Corporate Broking

 

+44 (0)207 220 0500

www.finncap.com

TB Cardew

 

Shan Shan Willenbrock/

+ 44 (0)7775 848537

Olivia Rosser

+ 44 (0)7552 864250

 

innovaDerma@tbcardew.com

 

 

 

Non-Executive Chairman's statement

 

I am pleased to deliver the Company's interim results for the period ended 31 December 2021.

 

The Company's change in strategy, to concentrate on driving increased profitable sales, ceasing loss making promotions and prioritising Skinny Tan, has been endorsed by the improvement in the Company's operating performance for the six months to 31 December 2021, as outlined in the Trading Update issued on 12 January 2022 and in the interim results announced today.

 

I am pleased to be able to report an improvement in gross margin, EBITDA and EPS.

 

 

Strategic report: Chief Executive's report

 

As previously detailed in our annual results published in December, the Group has implemented a number of necessary operational and financial interventions to transform and future-proof the business. The action plan focused on:

 

1.   Optimising our organisation

 

Our business is only as strong as our people and how they collaborate as a team. The focus remains to ensure that we have the right people, in the right country, with the right skills, focused on the right targets and powered by the right mindset.

 

2.   Strengthen our financial foundations

 

During H1 21 we have significantly reduced the EBITDA loss versus the prior year, with a laser-like focus on improving gross margins, reducing non-productive inventory, cutting low return costs and introducing real time accurate financial profitability metrics.

 

3.   Focusing our resources on our priority brands

 

Skinny Tan is our flagship brand and number one priority. Despite its ongoing success there remain significant profitable growth opportunities when compared to successful global beauty brands. Given the effects of the pandemic we have further strengthened our e-commerce foundations in the UK market, through the previously untapped potential of Amazon as a key driver of future profitable growth.

 

4.   Improve our customer experience online and in store

 

Our enhanced brand architecture and new packaging is rolling out on priority brands Skinny Tan and Charles + Lee, and we expect both to enhance the consumers' online and instore shopping experience. Initial consumer and retailer reaction to the new packaging, as well as our new product innovations for 2023, has been extremely positive..

 

5.   Modernising our customer acquisition marketing model

 

We now have in place a modern, nuanced digital marketing strategy that leverages the full gamut of digital media. As well as our expertise in social media advertising, the model now includes a strong focus on cost-effective e-mail marketing and high-return influencer marketing, all supported by a conversion optimised e-commerce site.

 

Our performance

 

Our strategy of driving increased profitable sales through gross margin improvement, radical simplification of business operations, rigorous cost control and the prioritisation of our Skinny Tan brand, is working.

 

Skinny Tan is the Company's largest brand (84% of revenue) and highest priority future growth driver. The previously communicated strategic decision to move away from certain loss leading sales led to a reduction in sales but is consistent with the Group's strategic focus on longer-term profitability. Amazon is now the Company's 3rd largest retailer, with further significant future growth anticipated as we enter the peak tanning season. This sales channel is becoming increasingly significant whilst allowing us to achieve a healthy margin.

 

Charles + Lee has shown excellent retail sales growth though revenues of c. £0.3m remain slightly below last year (H1 20: £0.4m) with the difference driven by shipment phasing. Positioned around 'No-nonsense, high-performance Aussie-made male grooming' we are successfully focusing the brand at the entry premium tier, adjusting pricing up c.10%, and with excellent growth potential.

 

Investment in Roots and Nuthing has been deprioritised as we focus on Skinny Tan and Charles + Lee as the Company's priority growth brands.

 

As previously announced, the Company entered into a Joint Venture for the Prolong brand in Dec 2021. Prolong revenues prior to the partnership agreement are included in our consolidated figures. Revenues after the partnership agreement are excluded from our consolidated figures and from future forecasts, however, InnovaDerma will directly benefit from any future dividends which are paid by the Joint Venture and/or any proceeds achieved by a future sale of the business.

 

Financial review

 

The Group has reported an increased gross profit of £2.1m, up 3.1% compared to the same period in the prior year, despite a decrease in revenue of 9.5% versus the previous year. This is due to a gross margin improvement of 690 basis points to 56.3% as the Group continues to focus on profitable sales, rather than revenue generation at the expense of profits.

 

Marketing efficiency continues to improve, to 38.1% (H1 21: 40.0%, H2 21: 39.2%), as the Group diversifies its digital strategy, including a strong focus on cost effective e-mail marketing and a conversion optimised e-commerce site, that goes beyond a pure Facebook play.

 

Adjusted EBITDA improved to £0.7m loss, as compared to £1.2m loss in the same period in the prior year, as a consequence of improved gross margin, diversified marketing strategy, greater recovery of e-commerce delivery costs, and tighter overhead cost control.

 

Cash

 

Cash reaches a seasonal low at the half year as we invest in appropriate levels of inventory ahead of the peak Skinny Tan UK sales peak months in H2. We reached this position at 31 December 2021 with cash at hand of £1.3m (H1 21: £0.15m), less structured, low-cost borrowings of £1.2m repayable in 2-5 years. The prior year cash position was achieved via extreme creditor position which precipitated the H2 21 fundraise.

 

Previous ad hoc funding, including seasonal invoice factoring, deferred VAT (COVID-19), and HMRC repayment plans, have been replaced by a single CBILS loan of £950k drawn down in full on 2 July 2021.

 

Dividends

 

The Board has elected not to declare an interim dividend.

 

 

Directors' report: Directors' responsibility statement

 

The Directors confirm that this condensed, consolidated interim financial information has been prepared in accordance with International Accounting Standard 34, 'Interim Financial Reporting', as adopted by the European Union, and that the half year management report herein includes a fair review of the information required by DTR 4.2.7 and DTR 4.2.8, namely:

 

·         An indication of important events that have occurred during the first six months and their impact on the condensed, consolidated interim financial information, and a description of the principal risks and uncertainties for the remaining six months of the financial year; and

·         Material related party transactions in the first six months and any material changes in the related party transactions described in the last annal report.

 

Unaudited consolidated statement of comprehensive income

For the six months ended 31 December 2021

 

 

 

Unaudited 6 months ended 31 December 2021

£'000

 

Unaudited 6 months ended 31 December 2020

(restated1)

£'000

 

Audited year ended 30 June 2021

£'000

 

 

 

 

 

 

 

Continuing operations

 

 

 

 

 

 

Revenue

 

3,689

 

4,077

 

10,211

Cost of sales

 

(1,613)

 

(2,064)

 

(4,421)

 

 

 

 

 

 

 

Gross profit

 

2,076

 

2,013

 

5,790

 

 

 

 

 

 

 

Marketing expenses

 

(1,405)

 

(1,632)

 

(4,036)

Wages and salaries expenses

 

(813)

 

(837)

 

(1,731)

Administrative expenses

 

(810)

 

(958)

 

(1,902)

 

 

 

 

 

 

-

 

 

 

 

 

 

 

Loss from operations

 

(952)

 

(1,414)

 

(1,879)

 

 

 

 

 

 

 

Finance credit / (cost)

 

2

 

-

 

(4)

 

 

 

 

 

 

 

Operating loss before tax

 

(950)

 

(1,414)

 

(1,883)

 

 

 

 

 

 

 

Taxation credit / (charge)

 

2

 

-

 

(371)

 

 

 

 

 

 

 

Operating loss after tax

 

(948)

 

(1,414)

 

(2,254)

 

 

 

 

 

 

 

Other comprehensive Income

 

 

 

 

 

 

Exchange income on foreign currency net investments

 

(6)

 

(16)

 

20

 

 

 

 

 

 

 

Total comprehensive expense for the period

 

(954)

 

(1,430)

 

(2,234)

 

 

 

 

 

 

 

Attributable to:

 

 

 

 

 

 

Owners of the parent

 

(942)

 

(1,394)

 

(2,246)

Non-controlling interests

 

(12)

 

(36)

 

12

 

 

 

 

 

 

 

Loss per share

 

 

 

 

 

 

Basic and diluted (£)

 

(0.03)

 

(0.10)

 

(0.13)

 

1 See note 2.3 for a description of the prior year restatement.

 

 

Unaudited consolidated Statement of Financial Position

As at 31 December 2021

 

 

 

£'000

Unaudited 31 December 2021

£'000

 

£'000

Unaudited 31 December 2020

(restated1)

£'000

 

£'000

Audited 30 June 2021

 

£'000

Non-current assets

 

 

 

 

 

 

 

 

 

Goodwill

 

 

214

 

 

439

 

 

439

Investments in associates

 

 

225

 

 

-

 

 

-

Other intangible assets

 

 

193

 

 

115

 

 

230

Property, plant and equipment

 

 

194

 

 

225

 

 

233

Deferred tax asset

 

 

-

 

 

382

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

826

 

 

1,161

 

 

902

 

 

 

 

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

1,333

 

 

151

 

 

2,338

 

Inventories

 

2,323

 

 

2,411

 

 

1,808

 

Trade and other receivables

 

1,369

 

 

991

 

 

1,896

 

 

 

 

 

 

 

 

 

 

 

 

 

5,025

 

 

3,553

 

 

6,042

 

 

 

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

 

 

Trade and other payables

 

(2,467)

 

 

(4,480)

 

 

(3,547)

 

Borrowings

 

(144)

 

 

-

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

(2,611)

 

 

(4,480)

 

 

(3,547)

 

 

 

 

 

 

 

 

 

 

 

Net current assets

 

 

2,414

 

 

(927)

 

 

2,495

 

 

 

 

 

 

 

 

 

 

Total assets less current liabilities

 

 

3,240

 

 

234

 

 

3,397

 

 

 

 

 

 

 

 

 

 

Non-current liabilities

 

 

 

 

 

 

 

 

 

Borrowings

 

(1,064)

 

 

-

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1,064)

 

 

-

 

 

-

 

 

 

 

 

 

 

 

 

 

Net assets

 

 

2,176

 

 

234

 

 

3,397

 

 

 

 

 

 

 

 

 

 

Equity

 

 

 

 

 

 

 

 

 

Share capital

 

 

2,916

 

 

1,738

 

 

2,859

Share premium account

 

 

11,380

 

 

8,288

 

 

11,193

Merger reserve

 

 

(721)

 

 

(721)

 

 

(721)

Foreign exchange reserve

 

 

276

 

 

246

 

 

282

Share-based payment reserve

 

 

16

 

 

10

 

 

10

Accumulated losses

 

 

(11,691)

 

 

(9,319)

 

 

(10,262)

 

 

 

 

 

 

 

 

 

 

Equity attributable to owners of parent

 

 

2,176

 

 

242

 

 

3,361

 

 

 

 

 

 

 

 

 

 

Non-controlling interest

 

 

-

 

 

(8)

 

 

36

 

 

 

 

 

 

 

 

 

 

Total equity

 

 

2,176

 

 

234

 

 

3,397

 

1 See note 2.3 for a description of the prior year restatement.

 

 

Unaudited consolidated Statement of Changes in Equity

For the six months ended 31 December 2021

 

Share capital

£'000

Share premium

£'000

Merger reserve

£'000

Foreign exchange reserve

£'000

Share-based payment reserve

£'000

Accumulated losses attributable to owners of parent

£'000

Equity attributable to owners of parent

£'000

Non-controlling interests

£'000

Total equity

£'000

 

 

 

 

 

 

 

 

 

 

Balance at 1 July 2021

2,859

11,193

(721)

282

10

(10,262)

3,361

36

3,397

 

 

 

 

 

 

 

 

 

 

Loss for the period

-

-

-

-

-

(936)

(936)

(12)

(948)

Exchange difference on translation of foreign operations

-

-

-

(6)

-

-

(6)

-

(6)

 

 

 

 

 

 

 

 

 

 

 

Total comprehensive income for the year

-

-

-

(6)

-

(936)

(942)

(12)

(954)

 

 

 

 

 

 

 

 

 

 

Issue of new shares

57

201

-

-

-

-

258

-

258

Issue costs related to equity

-

(14)

-

-

-

-

(14)

-

(14)

Share-based payment expense

-

-

-

-

6

-

6

-

6

Increase holding in subsidiary

-

-

-

-

-

(493)

(493)

(24)

(517)

 

 

 

 

 

 

 

 

 

 

Balance at 31 December 2021

2,916

11,380

(721)

276

16

(11,691)

2,176

-

2,176

 

 

 

 

 

 

 

 

 

 

Balance at 1 July 2020

1,738

8,288

(721)

262

78

(7,941)

1,704

28

1,732

 

 

 

 

 

 

 

 

 

 

Loss for the period

-

-

-

-

-

(1,378)

(1,378)

(36)

(1,414)

Exchange difference on translation of foreign operations

-

-

-

(16)

-

-

(16)

-

(16)

 

 

 

 

 

 

 

 

 

 

 

Total comprehensive income for the year

-

-

-

(16)

-

(1,378)

(1,394)

(36)

(1,430)

 

 

 

 

 

 

 

 

 

 

Share-based payment expense

-

-

-

-

(68)

-

(68)

-

(68)

 

 

 

 

 

 

 

 

 

 

Balance at 31 December 2020

1,738

8,288

(721)

246

10

(9,319)

242

(8)

234

 

 

 

 

 

 

 

 

 

 

Balance at 1 July 2020

1,738

8,288

(721)

262

78

(7,941)

1,704

28

1,732

 

 

 

 

 

 

 

 

 

 

Loss for the period

-

-

-

-

-

(2,266)

(2,266)

12

(2,254)

Exchange difference on translation of foreign operations

-

-

-

20

-

-

20

-

20

 

 

 

 

 

 

 

 

 

 

Total comprehensive income for the year

 

 

-

20

-

(2,266)

(2,246)

12

(2,234)

 

 

 

 

 

 

 

 

 

 

Issue of new shares

1,121

3,379

-

-

-

-

-

4,500

Issue costs deducted from equity

-

(474)

-

-

-

-

(474)

-

(474)

Share-based payment credit

-

-

-

-

(68)

-

(68)

-

(68)

Increase holding in subsidiary

-

-

-

-

-

(55)

(55)

(4)

(59)

 

 

 

 

 

 

 

 

 

 

Balance at 30 June 2021

2,859

11,193

(721)

282

10

(10,262)

3,361

36

3,397

 

1 See note 2.3 for a description of the prior year restatement.

 

Unaudited consolidated Statement of Cash Flows

For the six months ended 31 December 2021

 

 

 

£'000

Unaudited 6 months ended 31 December 2021
£'000

 

£'000

 

Unaudited 6 months ended 31 December 2020

(restated1)
£'000

 

£'000

Audited year ended 30 June 2021


£'000

 

 

 

 

 

 

 

 

 

 

Net cash (used in)/inflow from operating activities

 

 

(1,883)

 

 

(934)

 

 

(2,559)

 

 

 

 

 

 

 

 

 

 

Investing activities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Consideration paid for increased shareholding of subsidiary

 

-

 

 

-

 

 

(59)

 

Purchases of property, plant and equipment

 

(4)

 

 

(80)

 

 

(114)

 

Capitalisation of development costs

 

(37)

 

 

(71)

 

 

(220)

 

 

 

 

 

 

 

 

 

 

 

Net cash used in investing activities

 

 

(41)

 

 

(151)

 

 

(393)

 

 

 

 

 

 

 

 

 

 

Financing activities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net proceeds on issue of shares

 

-

 

 

-

 

 

3,526

 

Proceeds from borrowings

 

936

 

 

-

 

 

500

 

Interest received / (paid)

 

2

 

 

-

 

 

(4)

 

Cash divested on disposal of investment

 

(12)

 

 

-

 

 

-

 

 

 

 

 

 

 

 

 

 

 

Net cash generated/(used) from financing activities

 

 

926

 

 

-

 

 

4,022

 

 

 

 

 

 

 

 

 

 

Net increase/(decrease) in cash and cash equivalents

 

 

(998)

 

 

(1,085)

 

 

1,070

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents at beginning of year

 

 

2,338

 

 

1,241

 

 

1,241

 

 

 

 

 

 

 

 

 

 

Effect of foreign exchange rate changes

 

 

(7)

 

 

(5)

 

 

27

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents at end of year

 

 

1,333

 

 

151

 

 

2,338

 

1 See note 2.3 for a description of the prior year restatement.

 

 

Notes to the consolidated financial statements

For the six months ended 31 December 2021

 

1.         General information

 

InnovaDerma plc is a Group incorporated and domiciled in England and Wales under the Companies Act 2006. The address of its registered office is 27 Old Gloucester Street, London, United Kingdom, WC1N 3AX.

 

The principal activity of the Group is the development, distribution and sale of skincare, haircare, beauty and life science products in the markets that it operates.

 

2.         Accounting policies and critical accounting judgements

 

2.1 Basis of preparation

 

These financial statements are presented in pounds sterling because that is the currency of the primary economic environment in which the Group operates.

 

The Group's interim financial information has been prepared in accordance with IAS 34, 'Interim Financial Reporting as adopted by the EU.

 

The annual financial statements of the Group are prepared in accordance with the International Financial Reporting Standards ("IFRS") as adopted for use by the European Union. A copy of the statutory accounts for the year ended 30 June 2021 has been delivered to the Registrar of Companies. The auditor's report on those accounts was unqualified and did not contain any statements under Section 498(2) or (3) of the Companies Act 2006.

 

The same accounting policies, presentation and methods of computation have been followed in this unaudited interim financial information as those which were applied in the preparation of the Group's annual financial statements for the year ended 30 June 2021.

 

Certain new standards, amendments to standards and interpretations are not year effective for the year ended 30 June 2022 and have therefore not been applied in preparing this interim financial information.

 

The interim accounts are unaudited and do not constitute statutory accounts as defined in Section 434 of the Companies Act 2006.

 

2.2 Going concern

 

The Directors have, at the time of approving the financial statements, a reasonable expectation that the Company and the Group have adequate resources to continue in operational existence for the foreseeable future. In reaching this conclusion the Directors have considered the financial position of the Group, its cash, liquidity position and borrowing facilities together with its forecasts and projections for 12 months from the approval date that take into account reasonably possible changes in trading performance. The going concern basis of accounting has therefore continued to be adopted in preparing the financial statements.

 

The Group has taken into account the uncertainty due to the economic impact of COVID-19, and has made prudent forecasts, incorporating mitigating actions, based on current knowledge. It has also secured a CBILS loan of £950k, drawn down in full on 2 July 2021.

 

2.3 Prior year restatement

 

The Group has restated the prior year comparatives to correct the following prior period accounting errors:

·         To expense marketing costs incorrectly capitalised totalling £1,249k for the year ended 30 June 2018, £984k for the year ended 30 June 2019, and £840k for the year ended 30 June 2020.

·         Write down inventory due to incorrect allocation of cost of sales by £413k in the year ended 30 June 2019 and by £1,428k in the year ended 30 June 2020.

·         Reclassify Prolong intellectual property of £1,423k, prior to impairment, to goodwill to reflect the underlying nature of the April 2017 acquisition of Ergon Medical Limited.

·         Impairment of goodwill on acquisitions of £2,566k relating to Leimo / Grow Lase, Prolong and Stevie K, to correctly reflect the Group accounting policies.

·         An amortisation charge relating to intangible assets, totalling £489k for the year ended 30 June 2018, £235k for the year ended 30 June 2019, and £215k for the year ended 30 June 2020, to correctly reflect the Group accounting policies.

·         £701k reduction in goodwill of Skinny Tan, due to incorrect accounting for step acquisition of Skinny Tan Pty Ltd.

·         Register accruals totalling £392k for audit, tax and legal fees and bonus payments predominantly for the year ended 30 June 2020.

·         Recognise £140k expense relating to PAYE and VAT payments in the year ended 30 June 2019.

·         Recognise expense totalling £109k incorrectly recorded as prepayments in the year ended 30 June 2018 and £121k incorrectly recorded in the period ended 31 December 2020.

·         Register £60k bad debt provision relating to the year ended 30 June 2020.

·         Recognise £78k share-based payment expense in the statement of changes in equity for the year ended 30 June 2020, reallocated from the statement of comprehensive income.

·         £408k intercompany loan exchange movements reallocated from foreign exchange reserve to administrative expenses

·         Recognise amortisation of £32k and depreciation of £14k for the period ended 31 December 2020, not previously recorded.

·         Recognise corporation tax charges for the year ended 30 June 2017 of £217k and for the year ended 30 June 2018 of £118k.

·         Derecognise a deferred tax asset of £18k due to uncertainty of sufficient future profits in those subsidiaries.

·         To reclassify exceptional items of £196k and listing expenses of £76k to administrative expenses, and other operating income of £59k to cost of goods sold, in the period ended 31 December 2020.

·         Reduce corporation tax liability by £1,387k as a result of the above-listed adjustments.

·         Reduce the non-controlling interest by £184k as a result of the above-listed adjustments.

 

These changes have had a material impact on the Group's reported statement of comprehensive income and statement of financial position for the financial year 31 December 2020. Please refer to note 11 for further details of the restatement.

 

3.            Operating segments

 

The Group derives revenue from the sale of skin and beauty, haircare and life science products. The income streams are all derived from the utilisation of these products which, in all aspects except details are revenue, are reviewed and managed together within the Group and as such are considered to be only one segment.

 

A geographical analysis of the revenue from the Group's customers, by destination, is as follows:

 

 

Unaudited 6 months ended 31 December 2021

£'000

 

Unaudited 6 months ended 31 December 2020

(restated)

£'000

 

Audited year ended 30 June 2021

£'000

 

 

 

 

 

 

 

United Kingdom

 

2,754

 

2,833

 

7,919

United States of America

 

309

 

360

 

1,151

Asia Pacific

 

626

 

884

 

1,141

 

 

 

 

 

 

 

 

 

3,689

 

4,077

 

10,211

 

 

 

 

4.         Revenue 

The Group's revenues from products and services were as follows:

 

 

Unaudited 6 months ended 31 December 2021

£'000

 

Unaudited 6 months ended 31 December 2020

(restated)

£'000

 

Audited year ended 30 June 2021

£'000

 

 

 

 

 

 

 

Skin and beauty products

 

3,462

 

3,780

 

9,610

Haircare products

 

173

 

243

 

440

Life science devices

 

54

 

54

 

161

 

 

 

 

 

 

 

 

 

3,689

 

4,077

 

10,211

 

5.         Loss from operations

Loss before tax for the year has been arrived at after (crediting)/charging:

 

 

Unaudited 6 months ended 31 December 2021

£'000

 

Unaudited 6 months ended 31 December 2020

(restated)

£'000

 

Audited year ended 30 June 2021

£'000

 

 

 

 

 

 

 

Depreciation

 

43

 

17

 

35

Amortisation

 

50

 

58

 

116

Net foreign exchange losses/(gains)

 

(1)

 

(8)

 

140

Cost of inventories recognised as an expense

 

1,112

 

1,386

 

2,918

Non-recurring items including impairments, abortive and restructuring

35

 

196

 

210

Share-based payment expense

 

6

 

(68)

 

(68)

Directors' remuneration

 

224

 

155

 

438

Staff costs

 

807

 

905

 

1,731

 

Adjusted EBITDA

 

Adjusted EBITDA has been arrived at after accounting for:

 

 

Unaudited 6 months ended 31 December 2021

£'000

 

Unaudited 6 months ended 31 December 2020

(restated)

£'000

 

Audited year ended 30 June 2021

£'000

 

 

 

 

 

 

 

Operating loss before tax

 

(950)

 

(1,414)

 

(1,883)

 

 

 

 

 

 

 

Depreciation

 

43

 

17

 

35

Amortisation

 

50

 

58

 

116

Loss on disposal of investment

 

138

 

-

 

-

Foreign exchange losses/(gains) on intercompany loans

(16)

 

21

 

135

Non-recurring items including impairments, abortive and restructuring

35

 

196

 

210

Share-based payment (credit)/expense

 

6

 

(68)

 

(68)

 

 

 

 

 

 

 

Adjusted EBITDA

 

(694)

 

(1,190)

 

(1,455)

 

6.         Taxation

 

Analysis of tax (charge) / credit for the period:

 

7.         Losses per share

 

 

Unaudited 6 months ended 31 December 2021
£'000

 

 

Unaudited 6 months ended 31 December 2020

(restated)
£'000

 

Audited year ended 30 June 2021
£'000

Losses for the purposes of basic and diluted losses per share being net losses attributable to owners of the Group

 

942

 

1,394

 

2,246

 

 

 

 

 

 

 

 

 

2021

 

2020

 

2020

Number of shares

 

Number

 

Number

 

Number

Weighted average number of ordinary shares for the purposes of basic and diluted losses per share

 

27,378,386

 

14,496,633

 

17,449,621

 

Loss per share

 

 

 

Unaudited 6 months ended 31 December

2021

£
 

 

Unaudited 6 months ended 31 December

2020

(restated)

£
 

Audited year ended 30 June

2021

£

 

Basic and diluted

 

(0.03)

 

(0.10)

(0.13)

 

IAS 33 requires presentation of diluted EPS when a Group could be called upon to issue shares that would decrease earnings per share or increase the loss per share. For a loss-making Group with outstanding share options, the net loss per share would be decreased by the exercise of options. Therefore, as per IAS33:36, the anti-dilutive potential ordinary shares are disregarded in the calculation of diluted EPS.

 

8.         Notes to the cash flow statement

 

 

Unaudited 6 months ended 31 December 2021

£'000

 

Unaudited 6 months ended 31 December 2020

(restated)
£'000

 

Audited year ended 30 June 2021

£'000

 

 

 

 

 

 

 

Operating loss before tax

 

(950)

 

(1,414)

 

(1,883)

 

 

 

 

 

 

 

Adjustments for:

 

 

 

 

 

 

Finance costs

 

(2)

 

-

 

4

Depreciation

 

43

 

17

 

35

Amortisation

 

50

 

58

 

116

Loss on disposal of investment

 

138

 

-

 

-

Share-based payment expense

 

6

 

(68)

 

(68)

 

 

 

 

 

 

 

Operating cash flows before movements in working capital

 

(715)

 

(1,407)

 

(1,796)

 

 

 

 

 

 

 

Decrease / (increase) in inventories

 

(515)

 

(1,136)

 

(533)

Decrease / (increase) in receivables

 

527

 

599

 

(306)

(Decrease) / increase in payables

 

(1,080)

 

1,010

 

77

 

 

 

 

 

 

 

Cash used in operations

 

(1,783)

 

(934)

 

(2,558)

 

 

 

 

 

 

 

Income taxes received / (paid)

 

(100)

 

-

 

(1)

 

 

 

 

 

 

 

Net cash used in operating activities

 

(1,883)

 

(934)

 

(2,559)

 

 

 

 9.           Related party transactions

 

On 3 December 2021, Ergon Medical Limited, a wholly owned subsidiary of InnovaDerma plc, subdivided its 3,614 £1 Ordinary A shares into £0.10 shares and re-designated them Ordinary B shares and issued 51,060 new Ordinary A shares to Mark Ward, Non-Executive Director of InnovaDerma plc. The issue of new shares dilutes InnovaDerma plc's shareholding in Ergon Medical Limited to 45%. The transaction is an effective step disposal and as such Ergon Medical Limited is now an associate rather than a subsidiary of InnovaDerma plc.

 

On 3 December 2021, InnovaDerma plc signed a deed of release forgiving in full debt totalling £805,310 owed by the Ergon Medical Limited to InnovaDerma plc and its subsidiaries. It is this debt forgiveness that gives rise to the loss on disposal of investment in the period.

 

Other than those disclosed within this note, there have been no other transactions with related parties.

 

10.          Events after the reporting date

 

The Directors confirm that there are no events after the reporting date which require disclosure.

 

11.       Prior period restatement

 

The comparative figures for the six months ended 31 December 2020 have been restated to correct the prior period accounting errors disclosed in note 2.3. The following tables show the financial impact of the restatements by comparing the previously stated and the now restated Statement of Comprehensive Income and Statement of Financial Position.

 

 

As reported 6 months ended 31 December 2020

£'000

Restatements 2020

£'000

As restated 6 months ended 31 December 2020

£'000

 

 

 

 

Continuing operations

 

 

 

Revenue

4,145

(68)

4,077

Cost of sales

(2,078)

14

(2,064)

 

 

 

 

Gross profit

2,067

(54)

2,013

 

 

 

 

Other operating income

59

(59)

-

Listing expenses

(76)

76

-

Marketing expenses

(1,626)

(6)

(1,632)

Wages & salaries expenses

(906)

69

(837)

Administrative expenses

(544)

(414)

(958)

Exceptional items

(196)

196

-

 

 

 

 

Operating loss

(1,222)

(192)

(1,414)

 

 

 

 

Finance cost

-

-

-

 

 

 

 

Operating loss before tax

(1,222)

(192)

(1,414)

 

 

 

 

Income Tax expense

173

(173)

-

 

 

 

 

Net loss for the period

(1,049)

(365)

(1,414)

 

 

 

 

Other comprehensive Income

6

(6)

-

 

 

 

 

Exchange loss on foreign currency net investments

-

(16)

(16)

 

 

 

 

Total comprehensive income for the period

(1,043)

(387)

(1,430)

 

 

 

 

Attributable to:

 

 

 

Owners of the parent

(1,020)

(374)

(1,394)

Non-controlling interests

(23)

(13)

(36)

 

 

 

 

Loss per share

 

 

 

 -   basic and diluted (£)

(0.07)

(0.03)

(0.10)

 

 

 

 

 

 

 

 

 

£'000

As reported as at 31 December 2020

£'000

 

£'000

Restatements 2020

£'000

 

£'000

As restated as at 31 December 2020

£'000

Non-current assets

 

 

 

 

 

 

 

 

Intangible assets

 

8,003

 

 

(8,003)

 

 

-

Goodwill

 

-

 

 

439

 

 

439

Other intangible assets

 

-

 

 

115

 

 

115

Property, plant and equipment

 

157

 

 

68

 

 

225

Deferred tax asset

 

400

 

 

(18)

 

 

382

Other assets

 

16

 

 

(16)

 

 

-

 

 

 

 

 

 

 

 

 

 

 

8,576

 

 

(7,415)

 

 

1,161

 

 

 

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

 

 

Cash and cash equivalents

156

 

 

(5)

 

 

151

 

Inventories

4,142

 

 

(1,731)

 

 

2,411

 

Trade and other receivables

725

 

 

266

 

 

991

 

Prepayments and other assets

500

 

 

(500)

 

 

-

 

 

 

 

 

 

 

 

 

 

 

5,523

 

 

(1,970)

 

 

3,553

 

 

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

 

Trade and other payables

(4,745)

 

 

265

 

 

(4,480)

 

 

 

 

 

 

 

 

 

 

Net current assets

 

778

 

 

(1,705)

 

 

(927)

 

 

 

 

 

 

 

 

 

Total assets less current liabilities

 

9,354

 

 

(9,120)

 

 

234

 

 

 

 

 

 

 

 

 

Non-current liabilities

 

 

 

 

 

 

 

 

Borrowings

 

(1)

 

 

1

 

 

-

 

 

 

 

 

 

 

 

 

Net assets

 

9,353

 

 

(9,119)

 

 

234

 

 

 

 

 

 

 

 

 

Equity

 

 

 

 

 

 

 

 

Share capital

 

1,736

 

 

2

 

 

1,738

Share premium account

 

8,288

 

 

-

 

 

8,288

Merger reserve

 

(721)

 

 

-

 

 

(721)

Foreign exchange reserve

 

(162)

 

 

408

 

 

246

Share-based payment reserve

 

-

 

 

10

 

 

10

Accumulated profit/(loss)

 

36

 

 

(9,355)

 

 

(9,319)

 

 

 

 

 

 

 

 

 

Equity attributable to owners of parent

 

9,177

 

 

(8,935)

 

 

242

 

 

 

 

 

 

 

 

 

Non-controlling interest

 

176

 

 

(184)

 

 

(8)

 

 

 

 

 

 

 

 

 

Total equity

 

9,353

 

 

(9,119)

 

 

234

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IR JMMMTMTIJTIT ]]>
TwitterFacebookLinkedIn